Search
Results: 5
C5a anaphylatoxin and its role in critical illness-induced organ dysfunction.
Alexander Jt Wood, Arlette Vassallo, Charlotte Summers, Edwin R Chilvers, Andrew Conway-Morris
Nov 19, 2018
C5a complement Critical Illness immunosuppression Infection neutrophil Anaphylatoxins Blood Coagulation Blood Platelets cardiovascular system Cell Communication Complement C5a Critical Illness Endothelium Vascular Humans Immune System Diseases Immunity Innate Multiple Organ Failure Receptor Anaphylatoxin C5a
Predictive value of cell-surface markers in infections in critically ill patients
Andrew Conway Morris, Deepankar Datta, Manu Shankar-Hari, Christopher J Weir, Jillian Rennie, Jean Antonelli, Adriano G Rossi, Noel Warner, Jim Keenan, Alice Wang, K Alun Brown, Sion Lewis, Tracey Mare, A John Simpson, Gillian Hulme, Ian Dimmick, Timothy S Walsh
Oct 24, 2016
immunology Infectious Diseases Adolescent Biomarkers Critical Illness Cross Infection Female HLA-DR Antigens Humans Immune System Intensive Care Units Length of Stay Male Membrane Proteins Monocytes Neutrophils Prospective Studies Receptor Anaphylatoxin C5a Research Design Respiration Artificial Risk Factors T-Lymphocytes Regulatory
Cell-surface signatures of immune dysfunction risk-stratify critically ill patients
Andrew Conway Morris, Deepankar Datta, Manu Shankar-Hari, Jacqueline Stephen, Christopher J Weir, Jillian Rennie, Jean Antonelli, Anthony Bateman, Noel Warner, Kevin Judge, Jim Keenan, Alice Wang, Tony Burpee, K Alun Brown, Sion M Lewis, Tracey Mare, Alistair I Roy, Gillian Hulme, Ian Dimmick, Adriano G Rossi, A John Simpson, Timothy S Walsh
Jul 18, 2018
Cross Infection Immunoparesis Immunophenotyping Monocytes Neutrophils T-Lymphocytes Regulatory Aged Critical Illness Female HLA-DR Antigens Humans Immune System Diseases Intensive Care Units Male Middle Aged Predictive Value of Tests Prospective Studies Receptor Anaphylatoxin C5a Risk Assessment T-Lymphocytes Regulatory
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
David RW Jayne, Annette N Bruchfeld, Lorraine Harper, Matthias Schaier, Michael C Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimír Tesař, Mårten Segelmark, Antonia Potarca, Thomas J Schall, Pirow Bekker, CLEAR Study Group
May 13, 2019
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168)...
ANCA ANCA-associated vasculitis avacopan complement complement 5a complement 5a receptor Adult Aged Aniline Compounds Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis cyclophosphamide Double-Blind Method Drug Therapy Combination Female Glucocorticoids Humans Immunosuppressive Agents Male Middle Aged Nipecotic Acids prednisone Receptor Anaphylatoxin C5a Rituximab Severity of Illness Index
Avacopan for the Treatment of ANCA-Associated Vasculitis.
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: In this randomized, controlled trial, we assigned patients with...
Administration Oral Aniline Compounds Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Azathioprine cyclophosphamide Double-Blind Method Drug Therapy Combination Female Glucocorticoids Humans Immunosuppressive Agents Kaplan-Meier Estimate Male Middle Aged Nipecotic Acids prednisone Receptor Anaphylatoxin C5a Recurrence Remission Induction Rituximab